Drugs / ABBV-428
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02955251 | Nov 2016 → Oct 2019 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-428 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02955251 ↗ |
| Action | Activate | “tumor microenvironment-dependent CD40 activation” PMID 33608377 ↗ Feb 2021 |
| Route | Intravenous | “ABBV-428 was administered intravenously every 2 weeks to patients with advanced solid tumors.” PMID 33608377 ↗ Feb 2021 |
| Target | CD40 | “ABBV-428, a first-in-class, mesothelin-targeted, bispecific antibody designed for tumor microenvironment-dependent CD40 activation” PMID 33608377 ↗ Feb 2021 |